Trial ID or NCT#

NCT03180528

Status

RECRUITING

Purpose

This phase II trial studies how well remetinostat works in treating patients with skin basal cell cancer. Remetinostat may slow the growth of basal cell cancer cells.

Official Title

A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Kavita Sarin, MD, PhD
Dermatologist, General dermatologist, Cutaneous oncology specialist
Assistant Professor of Dermatology at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Irene Bailey-Healy
(650) 721-7149